TrialThe New England journal of medicine2025

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

Jennifer A Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.